Johnson & Johnson Gross Margin 2010-2024 | JNJ
Current and historical gross margin for Johnson & Johnson (JNJ) over the last 10 years. The current gross profit margin for Johnson & Johnson as of March 31, 2024 is %.
| Johnson & Johnson Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2024-03-31 |
$81.80B |
$57.13B |
69.84% |
| 2023-12-31 |
$85.16B |
$58.61B |
68.82% |
| 2023-09-30 |
$84.18B |
$58.06B |
68.97% |
| 2023-06-30 |
$82.82B |
$57.13B |
68.99% |
| 2023-03-31 |
$81.31B |
$55.92B |
68.77% |
| 2022-12-31 |
$79.99B |
$55.39B |
69.25% |
| 2022-09-30 |
$77.21B |
$54.02B |
69.96% |
| 2022-06-30 |
$80.55B |
$56.28B |
69.87% |
| 2022-03-31 |
$79.85B |
$55.91B |
70.02% |
| 2021-12-31 |
$78.74B |
$55.34B |
70.28% |
| 2021-09-30 |
$91.45B |
$61.73B |
67.51% |
| 2021-06-30 |
$89.19B |
$59.75B |
67.00% |
| 2021-03-31 |
$84.21B |
$55.79B |
66.24% |
| 2020-12-31 |
$82.58B |
$54.16B |
65.58% |
| 2020-09-30 |
$80.86B |
$53.11B |
65.68% |
| 2020-06-30 |
$80.50B |
$52.86B |
65.66% |
| 2020-03-31 |
$82.73B |
$54.73B |
66.15% |
| 2019-12-31 |
$82.06B |
$54.50B |
66.42% |
| 2019-09-30 |
$81.71B |
$54.32B |
66.49% |
| 2019-06-30 |
$81.33B |
$54.22B |
66.67% |
| 2019-03-31 |
$81.59B |
$54.50B |
66.80% |
| 2018-12-31 |
$81.58B |
$54.49B |
66.79% |
| 2018-09-30 |
$81.38B |
$53.99B |
66.35% |
| 2018-06-30 |
$80.68B |
$52.96B |
65.64% |
| 2018-03-31 |
$78.69B |
$52.05B |
66.14% |
| 2017-12-31 |
$76.45B |
$51.01B |
66.72% |
| 2017-09-30 |
$74.36B |
$50.54B |
67.97% |
| 2017-06-30 |
$72.53B |
$50.15B |
69.15% |
| 2017-03-31 |
$72.17B |
$50.31B |
69.70% |
| 2016-12-31 |
$71.89B |
$50.10B |
69.69% |
| 2016-09-30 |
$71.60B |
$49.77B |
69.52% |
| 2016-06-30 |
$70.88B |
$49.32B |
69.58% |
| 2016-03-31 |
$70.18B |
$48.60B |
69.25% |
| 2015-12-31 |
$70.07B |
$48.54B |
69.27% |
| 2015-09-30 |
$70.52B |
$48.80B |
69.20% |
| 2015-06-30 |
$71.88B |
$49.99B |
69.55% |
| 2015-03-31 |
$73.59B |
$51.02B |
69.33% |
| 2014-12-31 |
$74.33B |
$51.59B |
69.40% |
| 2014-09-30 |
$74.43B |
$51.58B |
69.30% |
| 2014-06-30 |
$73.54B |
$50.75B |
69.01% |
| 2014-03-31 |
$71.92B |
$49.68B |
69.07% |
| 2013-12-31 |
$71.31B |
$48.97B |
68.67% |
| 2013-09-30 |
$70.52B |
$48.13B |
68.25% |
| 2013-06-30 |
$69.99B |
$47.35B |
67.65% |
| 2013-03-31 |
$68.59B |
$46.29B |
67.49% |
| 2012-12-31 |
$67.22B |
$45.57B |
67.78% |
| 2012-09-30 |
$65.92B |
$44.93B |
68.15% |
| 2012-06-30 |
$64.87B |
$44.41B |
68.45% |
| 2012-03-31 |
$65.00B |
$44.50B |
68.46% |
| 2011-12-31 |
$65.03B |
$44.67B |
68.69% |
| 2011-09-30 |
$64.42B |
$44.36B |
68.86% |
| 2011-06-30 |
$63.40B |
$43.81B |
69.11% |
| 2011-03-31 |
$62.13B |
$43.09B |
69.35% |
| 2010-12-31 |
$61.59B |
$42.80B |
69.49% |
| 2010-09-30 |
$62.49B |
$43.43B |
69.49% |
| 2010-06-30 |
$62.59B |
$43.69B |
69.80% |
| 2010-03-31 |
$62.50B |
$43.78B |
70.04% |
| 2009-12-31 |
$61.90B |
$43.45B |
70.20% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$348.093B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
